Investor's Business Daily on MSN
Why psychedelics-tied Compass Pathways reversed its premarket losses
Compass Pathways stock reversed higher Tuesday on positive test results for its psychedelic drug in treatment-resistant depression.
Compass Pathways (NASDAQ:CMPS) said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety ...
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...
Earlier in July 2026, COMPASS Pathways reported 26-week data from its second Phase 3 COMP006 trial of COMP360 psilocybin in ...
16don MSN
Compass Pathways highlights long-term data from resistant depression, backs 2027 launch timeline
Compass Pathways plc CMPS on Wednesday reported 26-week results from Part B of its Phase 3 COMP006 trial, reinforcing the rapid and durable efficacy of COMP360, its synthetic psilocybin therapy for ...
Compass Pathways plc upgraded to Strong Buy after phase 3 COMP360 TRD data & fast-track FDA NDA review; see catalysts, timeline, & upside. Click for a CMPS stock update.
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc ...
While about 100 clinical trials focused on psychedelic compounds are chugging along in the regulatory pathway to examine the potential the drugs have to treat illnesses like depression and alcoholism, ...
Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June LONDON & NEW YORK--(BUSINESS WIRE)--Compass ...
Artificial Intelligence (AI) is rapidly penetrating a number of different sectors, including healthcare. The use of AI in mental health has opened up the possibility of new avenues of care, ...
Compass Pathways (CMPS) stock gains as Evercore ISI upgraded the company on the latest Phase 3 trial data for the company's psychedelic therapy COMP360. Read more here.
Compass Pathways has settled into three different bullish patterns on the weekly chart. The stock has shown relative strength compared to the general markets. Get the Strategy to Trade Pre-Fed Setups ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results